Stock Track | GoodRx Holdings Plummets 5.11% as Analysts Cut Price Targets Following Q3 Earnings

Stock Track11-07

Shares of GoodRx Holdings, Inc. (GDRX) plunged 5.11% in Thursday's trading session, as multiple analysts adjusted their price targets downward following the company's third-quarter earnings release. The stock's sharp decline reflects growing investor concerns about the company's near-term prospects.

UBS analyst Kevin Caliendo maintained a Hold rating on GoodRx but lowered the price target from $4.25 to $4. Similarly, Mizuho cut its target price for the stock from $5 to $4, while maintaining a Neutral rating. These downward revisions suggest that analysts are becoming more cautious about GoodRx's valuation and growth potential.

The company's Q3 2025 earnings report, released earlier, appears to have failed to impress investors and analysts alike. While specific details of the earnings were not provided, the subsequent analyst actions and stock price movement indicate that the results may have fallen short of expectations or raised concerns about the company's future performance. Investors are advised to closely monitor further analyst reports and company statements for a more comprehensive understanding of GoodRx's financial health and growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167721902?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167721902","market":"hk","top_or_hot":-1,"title":"Stock Track | GoodRx Holdings Plummets 5.11% as Analysts Cut Price Targets Following Q3 Earnings","media":"Stock Track","content":"<p>Shares of GoodRx Holdings, Inc. (GDRX) plunged 5.11% in Thursday's trading session, as multiple analysts adjusted their price targets downward following the company's third-quarter earnings release. The stock's sharp decline reflects growing investor concerns about the company's near-term prospects.</p>\n\n<p>UBS analyst Kevin Caliendo maintained a Hold rating on GoodRx but lowered the price target from $4.25 to $4. Similarly, Mizuho cut its target price for the stock from $5 to $4, while maintaining a Neutral rating. These downward revisions suggest that analysts are becoming more cautious about GoodRx's valuation and growth potential.</p>\n\n<p>The company's Q3 2025 earnings report, released earlier, appears to have failed to impress investors and analysts alike. While specific details of the earnings were not provided, the subsequent analyst actions and stock price movement indicate that the results may have fallen short of expectations or raised concerns about the company's future performance. Investors are advised to closely monitor further analyst reports and company statements for a more comprehensive understanding of GoodRx's financial health and growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GoodRx Holdings Plummets 5.11% as Analysts Cut Price Targets Following Q3 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GoodRx Holdings Plummets 5.11% as Analysts Cut Price Targets Following Q3 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 00:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of GoodRx Holdings, Inc. (GDRX) plunged 5.11% in Thursday's trading session, as multiple analysts adjusted their price targets downward following the company's third-quarter earnings release. The stock's sharp decline reflects growing investor concerns about the company's near-term prospects.</p>\n\n<p>UBS analyst Kevin Caliendo maintained a Hold rating on GoodRx but lowered the price target from $4.25 to $4. Similarly, Mizuho cut its target price for the stock from $5 to $4, while maintaining a Neutral rating. These downward revisions suggest that analysts are becoming more cautious about GoodRx's valuation and growth potential.</p>\n\n<p>The company's Q3 2025 earnings report, released earlier, appears to have failed to impress investors and analysts alike. While specific details of the earnings were not provided, the subsequent analyst actions and stock price movement indicate that the results may have fallen short of expectations or raised concerns about the company's future performance. Investors are advised to closely monitor further analyst reports and company statements for a more comprehensive understanding of GoodRx's financial health and growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GDRX","symbol_name":"GoodRx Holdings, Inc.","start_time":0,"source_url":"","article_id":"1167721902","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167721902","pubTimestamp":1762445808,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GoodRx Holdings, Inc. (GDRX) plunged 5.11% in Thursday's trading session, as multiple analysts adjusted their price targets downward following the company's third-quarter earnings release....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GDRX":"GoodRx Holdings, Inc."},"translate_title":"股票追踪|GoodRx Holdings暴跌5.11%，分析师在第三季度财报公布后下调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GDRX":1},"content_text":"Shares of GoodRx Holdings, Inc. (GDRX) plunged 5.11% in Thursday's trading session, as multiple analysts adjusted their price targets downward following the company's third-quarter earnings release. The stock's sharp decline reflects growing investor concerns about the company's near-term prospects.\nUBS analyst Kevin Caliendo maintained a Hold rating on GoodRx but lowered the price target from $4.25 to $4. Similarly, Mizuho cut its target price for the stock from $5 to $4, while maintaining a Neutral rating. These downward revisions suggest that analysts are becoming more cautious about GoodRx's valuation and growth potential.\nThe company's Q3 2025 earnings report, released earlier, appears to have failed to impress investors and analysts alike. While specific details of the earnings were not provided, the subsequent analyst actions and stock price movement indicate that the results may have fallen short of expectations or raised concerns about the company's future performance. Investors are advised to closely monitor further analyst reports and company statements for a more comprehensive understanding of GoodRx's financial health and growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167721902","isCrawlerRequest":true}